A pioneer in cancer vaccine development, AVAX Technologies, Inc. is an internationally integrated biotechnology company focused on developing and commercializing its AC Vaccine® technology for the treatment of cancer. Although subject to the same FDA regulations as other biological products, vaccines are inherently more difficult to develop, characterize, and manufacture than most pharmaceutical products. Vaccine development and commercialization is a long complex process. Avax is a leader in terms of stage of development and commercial readiness in the immuno-oncology arena. Today, the GMP approved facility is in Philadelphia and represents one of the very few autologous vaccine approved production facilities in the world. www.avax-tech.com